Article: CyDex Pharmaceuticals Presents Phase 2 Clinical Trial Results for Captisol-Enabled[R] Budesonide/Azelastine Combination Solution Nasal Spray at American Academy of Allergy Asthma and Immunology AAAAI Meeting.(Clinical report)

CyDex Pharmaceuticals, Inc. announced the presentation of Phase 2 clinical trial results of its novel, proprietary Captisol-Enabled[R] budesonide/azelastine nasal spray (CDX-313) for seasonal allergic rhinitis (SAR). The budesonide/azelastine combination nasal spray demonstrated statistically significant improved results over a nasal spray placebo (see also CyDex Pharmaceuticals, Inc.).

A randomized, double-blind, placebo-controlled, three-way cross-over study was conducted in 108 SAR patients to compare the relative efficacy of Captisol-Enabled Budesonide + Azelastine Nasal Spray (Single Solution) and Rhinocort Aqua[R]/ (Suspension) + Astelin[R] Nasal Spray ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!